Core Insights - Creative Realities, Inc. reported a quarterly loss of $0.32 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.08, marking an earnings surprise of -300.00% [1] - The company's revenues for the quarter ended September 2025 were $10.55 million, missing the Zacks Consensus Estimate by 19.18%, and down from $14.44 million a year ago [2] - The stock has gained approximately 13.9% year-to-date, underperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is breakeven on revenues of $16.25 million, while for the current fiscal year, it is $0.07 on revenues of $52.06 million [7] Estimate Revisions - Prior to the earnings release, the trend for estimate revisions was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] Industry Context - The Internet - Software industry, to which Creative Realities, Inc. belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.18 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to a loss of $5.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -41.56%. A quarter ago, it was expected that this company would post a loss of $2.3 per share when it actually produced a loss of $2.45, delivering a surprise of -6.52%.Over the last four quarters, the company ...

Core Insights - Stereotaxis Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.06, marking a 50% earnings surprise [1] - The company generated revenues of $7.46 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 13.21% and down from $9.2 million a year ago [2] - Stereotaxis shares have increased by approximately 22.4% year-to-date, outperforming the S&P 500's gain of 16.2% [3] Earnings Outlook - The earnings outlook for Stereotaxis is crucial for investors, with current consensus EPS estimates at -$0.06 for the next quarter and -$0.23 for the current fiscal year [7] - The company holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Stereotaxis belongs, is currently in the top 25% of Zacks industries, suggesting a favorable environment for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Hallador Energy reported quarterly earnings of $0.55 per share, significantly exceeding the Zacks Consensus Estimate of $0.06 per share, representing an earnings surprise of +816.67% [1] - The company achieved revenues of $146.85 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 27.42%, compared to $105.04 million in the same quarter last year [2] - Hallador Energy has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has increased approximately 71.8% since the beginning of the year, outperforming the S&P 500's gain of 14.4% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.04 for the upcoming quarter and $0.53 for the current fiscal year [4][7] - The Zacks Industry Rank indicates that the Alternative Energy - Other sector is currently in the bottom 36% of over 250 Zacks industries, which may impact Hallador Energy's stock performance [8]

FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $4.01. This compares to a loss of $4.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +59.85%. A quarter ago, it was expected that this biotech drug developer would post a loss of $2.25 per share when it actually produced a loss of $3.38, delivering a surprise of -50.22%.Over the last four quarters, the company ...

Exodus Movement, Inc. (EXOD) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5,400.00%. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced earnings of $1.12, delivering a surprise of +1500%.Over the last four quar ...

Financial Performance - Arcturus Therapeutics reported a quarterly loss of $0.49 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of +60.80% [1] - The company posted revenues of $17.15 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 50.63%, although this is a decline from $41.67 million in the same quarter last year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Arcturus Therapeutics shares have declined approximately 48.6% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.49 on revenues of $9.77 million, and for the current fiscal year, it is -$3.49 on revenues of $73.55 million [7] - The earnings outlook and estimate revisions will be crucial for assessing the stock's future performance [4][5] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcturus belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Arcturus may also be influenced by the overall industry trends and the performance of peer companies, such as TScan Therapeutics, which is expected to report a quarterly loss of $0.35 per share [9]

分组1 - Telos Corporation reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to a loss of $0.1 per share a year ago, representing an earnings surprise of +350.00% [1] - The company achieved revenues of $51.44 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 13.06%, and showing a significant increase from year-ago revenues of $23.78 million [2] - Telos has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] 分组2 - The stock has gained approximately 86.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $45.8 million, while for the current fiscal year, it is -$0.03 on revenues of $157.89 million [7] - The Computers - IT Services industry, to which Telos belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]

Core Insights - Envoy Medical, Inc. reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -29.63% [1] - The company generated revenues of $0.04 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 23.64% [2] - Envoy Medical's shares have declined approximately 50.9% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $0.06 million, and for the current fiscal year, it is -$1.17 on revenues of $0.2 million [7] Market Outlook - The earnings outlook and estimate revisions trend for Envoy Medical were favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The Medical - Instruments industry, to which Envoy Medical belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a positive industry outlook [8]

Core Insights - ReNew Energy Global PLC reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.17 per share, representing an earnings surprise of -23.53% [1] - The company posted revenues of $408 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.17% and showing an increase from $356 million year-over-year [2] - The stock has gained approximately 10.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 14.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $318 million, while for the current fiscal year, the estimate is $0.23 on revenues of $1.59 billion [7] - The estimate revisions trend for ReNew Energy Global was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Alternative Energy - Other industry, to which ReNew Energy Global belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]